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Introduction
Drospirenone is a synthetic progestin usually found in combination with
ethynilestradiol in oral contraceptive formulas. In 2007, this compound was
also used in hormonal replacement therapy during menopause. Drospirenone
shows antimineralocoricoı¨d effect due to an analogy of structure with aldosterone.
This effect counteracts the estrogen stimulating action of renin–angiotensin–
aldosterone (RAA) system, lowering water retention symptoms due to classic oral
contaception. On the other hand, primary aldosteronism (PA) accounts for 6% of
hypertension. Screening of PA consists in evaluation of PAC levels and ARR
after withdrawal of several antihypertensive drugs that can interfere with this
dosage.
Aim of the study
To evaluate the interference of drospirenone with plasma aldosterone
concentration (PAC), plasma renin activity (PRA) and potassium levels in the
general population. Blood sample was obtained in 25 patients taking an oral
contraception (11 in drospirenone group – 14 in non drospirenone group).
Comparison of PAC/PRA ratio (aldosterone to renin ratio – ARR) was also
performed as this ratio is used for screening of primary aldosteronism.
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Results
Age was comparable in both groups (PZ0.29). PAC was significantly more
elevated in patients taking drospirenone (PZ0.001) while potassium levels was
not significantly different (PZ0.2). Interestingly, PRA levels were not different
between both groups (PZ0.07). In consequence, PAC/PRA was significantly
increased in drospirenone group (PZ0.017). Systolic pressure was significantly
higher in drospirenone group while diastolic pressure was not different (PZ0.02
and PZ0.098 respectively). Median value of ARR in drospirenone group
was 22.63.
Conclusion
Drospirenone is an effective oral contraception with antimineralocorticoid effect
with the advantage of lowering water retention symptoms. In consequence of this
effect, we found a significantly higher PAC and ARR levels in drospirenone
group. Drospirenone should then be withdrawed before screening a patient in case
of primary aldosteronism suspicion.


